JP2023501781A5 - - Google Patents
Info
- Publication number
- JP2023501781A5 JP2023501781A5 JP2022525650A JP2022525650A JP2023501781A5 JP 2023501781 A5 JP2023501781 A5 JP 2023501781A5 JP 2022525650 A JP2022525650 A JP 2022525650A JP 2022525650 A JP2022525650 A JP 2022525650A JP 2023501781 A5 JP2023501781 A5 JP 2023501781A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- functional fragment
- administered
- baffr antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025225960A JP2026062653A (ja) | 2019-11-06 | 2025-12-03 | シェーグレン症候群の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931292P | 2019-11-06 | 2019-11-06 | |
| US62/931,292 | 2019-11-06 | ||
| PCT/US2020/057184 WO2021091706A1 (en) | 2019-11-06 | 2020-10-23 | Treatment for sjögren's syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025225960A Division JP2026062653A (ja) | 2019-11-06 | 2025-12-03 | シェーグレン症候群の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501781A JP2023501781A (ja) | 2023-01-19 |
| JP2023501781A5 true JP2023501781A5 (https=) | 2023-10-11 |
Family
ID=73449232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525650A Pending JP2023501781A (ja) | 2019-11-06 | 2020-10-23 | シェーグレン症候群の処置 |
| JP2025225960A Pending JP2026062653A (ja) | 2019-11-06 | 2025-12-03 | シェーグレン症候群の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025225960A Pending JP2026062653A (ja) | 2019-11-06 | 2025-12-03 | シェーグレン症候群の処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220356261A1 (https=) |
| EP (1) | EP4055047A1 (https=) |
| JP (2) | JP2023501781A (https=) |
| KR (1) | KR20220093347A (https=) |
| AU (2) | AU2020377872B2 (https=) |
| CA (1) | CA3160207A1 (https=) |
| WO (1) | WO2021091706A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021320129B2 (en) * | 2020-08-04 | 2025-12-18 | Novartis Ag | Treatment of B cell malignancies |
| WO2025083621A1 (en) * | 2023-10-20 | 2025-04-24 | Novartis Ag | Treatment of hidradenitis suppurativa using anti-baff-r antibodies |
| WO2025257781A1 (en) * | 2024-06-14 | 2025-12-18 | Novartis Ag | Treatment of systemic sclerosis using anti-baff-r antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0513100A (pt) * | 2004-07-22 | 2007-10-23 | Genentech Inc | métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados |
| SI2315780T1 (sl) | 2008-07-17 | 2015-11-30 | Novartis Ag | Sestavki in postopki uporabe za terapevtska protitelesa |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US9833519B2 (en) * | 2012-09-25 | 2017-12-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for the diagnosis and treatment of sjögren's syndrome |
| TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
-
2020
- 2020-10-23 KR KR1020227018625A patent/KR20220093347A/ko active Pending
- 2020-10-23 EP EP20807616.6A patent/EP4055047A1/en active Pending
- 2020-10-23 WO PCT/US2020/057184 patent/WO2021091706A1/en not_active Ceased
- 2020-10-23 CA CA3160207A patent/CA3160207A1/en active Pending
- 2020-10-23 JP JP2022525650A patent/JP2023501781A/ja active Pending
- 2020-10-23 US US17/773,935 patent/US20220356261A1/en active Pending
- 2020-10-23 AU AU2020377872A patent/AU2020377872B2/en active Active
-
2025
- 2025-04-09 AU AU2025202534A patent/AU2025202534A1/en active Pending
- 2025-12-03 JP JP2025225960A patent/JP2026062653A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501781A5 (https=) | ||
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| JP2022509358A5 (https=) | ||
| JP2009544619A5 (https=) | ||
| JP2010535805A5 (https=) | ||
| JP2011511071A5 (https=) | ||
| EP4125881B1 (en) | New use of angiotensin ii type 2 receptor agonist | |
| JP2016185995A5 (https=) | ||
| JP2007536311A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| JP2020503269A5 (https=) | ||
| JP2024530189A5 (https=) | ||
| JP2019507759A5 (https=) | ||
| JP2017533220A5 (https=) | ||
| JP2020500864A5 (https=) | ||
| JP2023517535A5 (https=) | ||
| JP2024016209A5 (https=) | ||
| JP2023530264A5 (https=) | ||
| JP2021509395A5 (https=) | ||
| JP2023539625A5 (https=) | ||
| JP2007500134A5 (https=) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2022041802A5 (https=) | ||
| Puri et al. | Expanding the domain of drug delivery for HIV prevention: exploration of the transdermal route | |
| JP2024517085A5 (https=) |